Latest Financial Results

Q3 2019

Quarterly Results

Ended Sep 30, 2019

Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.
Price
Change
Volume
Day Range
52 Week Range

Company Overview

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Additionally, Xenetic is leveraging PolyXen™, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen™ has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.

Contact Information

Investor Relations
Jenene Thomas Communications, LLC.
Jenene Thomas
T: 833-475-8247
xbio@jtcir.com

Transfer Agent
Empire Stock Transfer, Inc.
1859 Whitney Mesa Drive
Henderson, NV 89014
T: 702-818-5898